ABUS
Arbutus Biopharma Corp
4.50$
-4.1%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -467.7% | -806.2% | -1,259.5% | -840.3% | -1,548.6% | -655.3% | -759.1% | -146.7% | -1,099.6% | -445.3% | -4.5% | -593.5% | -13.6% | |
| 7.9% | 16.7% | 23.2% | 20.6% | 25.1% | 21.2% | 18.7% | 0.1% | 2.1% | 1.0% | 0.0% | 1.1% | 0.0% | |
| 53.3% | 80.3% | 131.5% | 184.2% | 161.3% | 103.7% | 202.0% | 8.0% | 238.8% | 120.1% | 0.8% | 160.3% | 3.0% | |
| -72.6% | 69.3% | -186.6% | 159.8% | -186.6% | -14.5% | 298.7% | -169.8% | 217.4% | 171.1% | -99.3% | -220.5% | -97.5% | |
| 0.7% | 0.6% | 6.2% | 0.1% | 0.0% | 5.5% | 0.0% | 0.0% | 0.0% | 0.0% | 4.5% | 587.0% | 7.7% | |
| 223.9% | 1,036.1% | 763.3% | 569.5% | -895.1% | 852.0% | 643.4% | 145.4% | -1,894.0% | -129.5% | 1.2% | -163.8% | -6.0% | |
| 36.1% | 177.5% | 1,594.6% | 1,411.9% | 132.6% | 90.3% | 157.8% | 4.2% | 159.5% | 156.0% | 6.5% | 310.5% | 9.5% | |
| -207.5% | 408.1% | 1,097.7% | 1,140.6% | -2,310.8% | 284.9% | 42.3% | 3.1% | -2,836.3% | -418.6% | 3.2% | -447.2% | -10.0% | |
| -468.4% | -806.2% | -1,265.7% | -840.4% | -1,548.6% | -660.8% | -759.1% | -146.7% | -1,099.6% | -445.3% | -4.5% | -593.5% | -13.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.